Management of myelofibrosis during pregnancy: A case report

Radmila Živković; Olivera Marković; Dragomir Marisavljević; Tatjana Terzić; Ljiljana Tukić

doi:10.2298/4193

Radmila Živković Department of Hematology, Clinical Hospital Center ”Bežanijska kosa“, Belgrade, Serbia
Olivera Marković Department of Hematology, Clinical Hospital Center ”Bežanijska kosa“, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Dragomir Marisavljević Department of Hematology, Clinical Hospital Center ”Bežanijska kosa“, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Tatjana Terzić Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Ljiljana Tukić Clinic of Hematology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia

DOI: https://doi.org/10.2298/4193

Keywords: myeloproliferative disorders, primary myelofibrosis, pregnancy, interferon-alpha, treatment outcome,

Abstract

Introduction. Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm that occurs most commonly in the decade six of life and it is very rare in the young persons. Case report. We reported a 28-year-old female patient with primary myelofibrosis who had a normal pregnancy and delivery in the week 40 of pregnancy without any complications. Two years before the diagnosis of PMF she had normal pregnancy. The patient was treated with interferon-alpha and low dose aspirin during the whole pregnancy and with low-molecular-weight heparin a week before delivery and 6 weeks after. The patient had no complications during pregnancy. She delivered in term with healthy, normal baby weight. Conclusion. Decision about treatment strategy of pregnancy associated hematologic malignancies should be made for each patient individually.

Author Biographies

Radmila Živković, Department of Hematology, Clinical Hospital Center ”Bežanijska kosa“, Belgrade, Serbia

Department of Hematology

Olivera Marković, Department of Hematology, Clinical Hospital Center ”Bežanijska kosa“, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Department of Hematology

Dragomir Marisavljević, Department of Hematology, Clinical Hospital Center ”Bežanijska kosa“, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Department of Hematology

References

Swerdlow SH, Campo E, Harris NL, Jaffe, ES, Pileri, SA, Stein, H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.

Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification and management. Am J Hematol 2011; 86(12): 1017−26.

Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 2008; 22(5): 235−45.

McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hema-tol Oncol 1997; 15(4): 173−89.

Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic mye-lofibrosis in pregnancy: a case report and review of the litera-ture. Am J Obstet Gynecol 1992; 167(1): 38−9.

Gotić M, Cvetković M, Bozanović T, Cemerikić V. Successful treatment of primary myelofibrosis with thrombocytosis dur-ing pregnancy with alfa-interferon. Srp Arh Celok Lek 2001; 129(11−12): 304−8.

Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haemat 2008; 142(3): 480−2.

Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombo-cythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 pa-tients. Clin Appl Thromb Hemost 2000; 6(1): 31−5.

Bai Y, Zhang C, Wang J, Liang M, Zhang X. Clinical analysis of eleven patients with chronic myeloproliferative disorders com-plicating pregnancy. Zhonghua Fu Chan Ke Za Zhi 2010; 45(12): 896−9.

Yazdani Brojeni P, Matok I, Garcia BF, Koren G. A systematic re-view of the fetal safety of interferon alpha. Reprod Toxicol 2012; 33(3): 265−8.

Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Heamtol 2009; 84(10): 636−40.

Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129(3): 293−306.

Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay J, et al. Allogeneic haematopoietic stem cell transplantation for mye-lofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152(3): 331−9.

Messa RA. New drugs for the treatment of myelofrosis. Curr Hematol Malig Rep 2010; 5(1): 15−21.

Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 222−30.

Hasselbalch HC. A new era for IFN-α in the treatment of Phila-delphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011; 4(6): 637−55.